Sod1 (Superoxide Dismutase 1) is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
Superoxide dismutase 1 (SOD1), also known as Cu/Zn superoxide dismutase, is a cytoplasmic enzyme that catalyzes the dismutation of superoxide radicals (O₂⁻) to molecular oxygen and hydrogen peroxide. Encoded by the SOD1 gene on chromosome 21q22.11, it is a critical component of the cellular antioxidant defense system. Mutations in SOD1 were the first genetic cause identified for [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- in 1993, and they remain one of the best-characterized genetic contributors to the disease, present in approximately 15–20% of familial ALS cases and 1–2% of all ALS cases 1(https://www.ncbi.nlm.nih.gov/books/NBK594270/) (Bayer TA et al., 2024).
SOD1-ALS has become a landmark in [precision medicine[/treatments/[precision-medicine[/treatments/[precision-medicine[/treatments/[precision-medicine--TEMP--/treatments)--FIX-- for neurodegeneration with the development and approval of [tofersen[/treatments/[tofersen[/treatments/[tofersen[/treatments/[tofersen--TEMP--/treatments)--FIX-- (Qalsody), an antisense oligonucleotide that targets SOD1 mRNA — the first genetically targeted therapy approved for ALS (Miller TM et al., 2022).
The SOD1 gene spans approximately 11 kb of genomic DNA and contains 5 exons. Over 200 distinct mutations have been identified across all five exons and the untranslated regions, nearly all of which are missense mutations that cause ALS through a toxic gain-of-function mechanism 2(https://www.nejm.org/doi/full/10.1056/NEJMoa2204705).
SOD1 is a homodimeric metalloenzyme consisting of two 153-amino acid subunits. Each subunit contains:
The mature, functional enzyme requires proper metal loading (metallation), disulfide bond formation, and dimerization. Disruption of any of these post-translational maturation steps promotes misfolding and aggregation 3(https://www.tandfonline.com/doi/full/10.1080/14737175.2024.2355983).
SOD1's primary function is to catalyze the conversion of toxic superoxide radicals into hydrogen peroxide and oxygen:
2 O₂⁻ + 2H⁺ → H₂O₂ + O₂
The hydrogen peroxide produced is subsequently detoxified by catalase and glutathione peroxidase. SOD1 accounts for approximately 80% of total SOD activity in the cell and is the major cytoplasmic antioxidant defense against superoxide 1(https://www.ncbi.nlm.nih.gov/books/NBK594270/).
Beyond its canonical antioxidant role, SOD1 has been implicated in:
| Mutation | Region | Frequency | Clinical Features |
|---|---|---|---|
| A4V | Exon 1 | Most common in N. America (~50%) | Aggressive, mean survival ~1.2 years |
| D90A | Exon 4 | Most common worldwide | Slower progression; recessive in Scandinavia |
| G93A | Exon 4 | Moderate frequency | Variable progression; basis of transgenic mouse model |
| H46R | Exon 2 | Common in Japan | Slow progression, lower limb onset |
| I113T | Exon 4 | Common in UK | Variable penetrance and progression |
| A89V | Exon 4 | Moderate | Variable |
SOD1 mutations cause ALS through a toxic gain-of-function rather than loss of enzymatic activity. Evidence supporting this includes:
Mutant SOD1 causes motor neuron degeneration through multiple interconnected mechanisms:
Mutations destabilize the SOD1 protein, promoting misfolding and the formation of toxic oligomers and aggregates. Misfolded SOD1 accumulates in:
Mutant SOD1 accumulates on the outer mitochondrial membrane and in the intermembrane space, where it:
Mutant SOD1 sensitizes motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- to [glutamate excitotoxicity[/mechanisms/[glutamate-excitotoxicity[/mechanisms/[glutamate-excitotoxicity[/mechanisms/[glutamate-excitotoxicity--TEMP--/mechanisms)--FIX-- by:
Misfolded SOD1 accumulation triggers the [unfolded protein response[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- and overwhelms the [ubiquitin-proteasome system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system--TEMP--/entities)--FIX-- and [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- pathways.
Motor neuron degeneration in SOD1-ALS involves dysfunction of surrounding glial cells:
[astrocytes): Mutant SOD1-expressing [astrocytes) are directly toxic to motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- through release of toxic factors
**[microglia[/[Oligodendrocytes[/[Oligodendrocytes[/[Oligodendrocytes[/[Oligodendrocytes[/[Oligodendrocytes[/[Oligodendrocytes[/Oligodendrocytes(https://www.nejm.org/doi/full/10.1056/NEJMoa2003715)):
April 2023: FDA accelerated approval for ALS associated with SOD1 mutations
July 2025: MHRA (UK) approval for SOD1-ALS
Administration: Intrathecal injection every 28 days (after loading doses)
Mechanism: Reduces SOD1 protein levels in CSF by ~30–40%
Clinical evidence: The Phase 3 VALOR trial showed tofersen reduced [neurofilament light chain ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- levels (a biomarker of neurodegeneration) by ~50% and CSF SOD1 protein by ~35%. The open-label extension with over 3.5 years of follow-up demonstrated that early tofersen initiation was associated with slower decline in clinical function, breathing, strength, and reduced risk of death or permanent ventilation 4(https://www.nejm.org/doi/full/10.1056/NEJMoa2204705) 5(https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.52264) (Neurology et al., 2025).
Real-world evidence from 2025 confirms sustained disease stabilization: patients showed mean serum [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- reduction of 57.9% and CSF pNFH reduction of 67.6%, with meaningful preservation of function 5(https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.52264) (Smith RA et al., 2025).
The SOD1-G93A mouse (also known as the hSOD1G93A or "SOD1 mouse") is the most widely used animal model of ALS. Created in 1994, it overexpresses human mutant SOD1 with the G93A substitution and develops progressive motor neuron degeneration with an ALS-like phenotype:
While invaluable for understanding disease mechanisms, the SOD1-G93A model has limitations: many therapies showing efficacy in this model have failed in human [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials, potentially due to the model's supraphysiological SOD1 expression levels and the lack of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- and [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- pathology that characterizes most ALS cases.
While SOD1 mutations are primarily associated with ALS, the protein and its dysfunction intersect with other [neurodegenerative ]:
The study of Sod1 (Superoxide Dismutase 1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.